Viatris Q3 adjusted EPS beats estimates; hikes forecast

Overview

• Healthcare company's Q3 revenue was flat yr/yr and missed analyst expectations

• Adjusted EPS for Q3 rose 6% and beat analyst expectations

• Company raised 2026 financial guidance midpoints for all key metrics

Outlook

• Viatris raises 2026 total revenue guidance midpoint to $14.8 bln from $14.75 bln

• Company lifts 2026 adjusted EBITDA guidance midpoint to $4.5 bln from $4.4 bln

• Viatris increases 2026 adjusted EPS guidance midpoint to $2.60 from $2.52

Result Drivers

• SUPPLY CONSTRAINTS AND COMPETITION - Co said supply constraints in Europe and Emerging Markets and increased competition offset growth from new products and Greater China

• NEW PRODUCT SALES - Co said new product sales contributed to revenue, primarily in Developed Markets

• GREATER CHINA BRANDS - Co said continued strength in Greater China brands supported revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Viatris Inc. is $20.00, about 4.1% above its November 4 closing price of $19.22

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads

• Nov 3 - Henry Schein Q3 sales slightly miss, raises 2026 profit outlook

• Nov 4 - Perrigo Q3 sales slightly beat expectations on market share gains

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)